NEW YORK, Dec 11 - Rosetta Inpharmatics said Monday that it had licensed its Resolver Expression Data Analysis System to Glaxo Wellcome.
Glaxo Wellcome will use the system, which is exclusively distributed by Agilent Technologies, to to analyze gene expression data.
The Resolver software can be used with a variety of DNA chip technologies, including Agilent’s microarrays and Affymetrix GeneChip microarrays.
" It significantly complements our in-house development programs and will help maintain the company's position at the leading edge of applying genomics technologies in the pursuit of new treatments,” said Eric Meldrum, group leader for molecular and cellular biology at Glaxo Wellcome.
Glaxo Wellcome was not immediately available to comment on its decision to license the Resolver software.